Biocept Company Profile (NASDAQ:BIOC)

Analyst Ratings

Consensus Ratings for Biocept (NASDAQ:BIOC) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.07 (354.25% upside)

Analysts' Ratings History for Biocept (NASDAQ:BIOC)
Show:
DateFirmActionRatingPrice TargetActions
6/6/2016Roth CapitalInitiated CoverageBuy$1.20View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Feltl & Co.DowngradeStrong-Buy -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/10/2016HC WainwrightReiterated RatingBuy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/21/2015AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Biocept (NASDAQ:BIOC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016Q216N/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2016Q116($0.23)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.26)($0.24)$76.00 million$218.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.22)($0.24)$165.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.23)($0.22)$19.25 million$76.77 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.61)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2015Q414($0.88)($0.87)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.82)($0.87)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/15/2014($0.67)($0.67)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biocept (NASDAQ:BIOC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.22)($0.22)($0.22)
Q3 20161($0.21)($0.21)($0.21)
Q4 20161($0.20)($0.20)($0.20)
Q1 20171($0.20)($0.20)($0.20)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.19)($0.19)($0.19)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biocept (NASDAQ:BIOC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Biocept (NASDAQ:BIOC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/4/2016Bruce GerhardtDirectorBuy25,000$1.00$25,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2016Claire ReissMajor ShareholderBuy614,273$1.00$614,273.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015David F HaleChairmanBuy40,000$1.25$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Marsha Alpert ChandlerDirectorBuy2,000$1.25$2,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Michael W NallCEOBuy12,000$1.25$15,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Biocept (NASDAQ:BIOC)
DateHeadline
07/27/16 08:36 PMBiocept Inc.: Biocept Appoints Timothy C. Kennedy as Chief ... - The Wall Street Transcript
07/27/16 11:20 AMGlobal Circulating Tumor Cells Market 2015 Analysis and Forecast to 2022
07/27/16 07:18 AMBiocept Appoints Timothy C. Kennedy as Chief Financial Officer and Senior Vice President of Operations - [at noodls] - SAN DIEGO, July 27, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces ...
07/27/16 07:11 AMBIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
07/27/16 07:10 AM8:10 am Biocept names Timothy C. Kennedy as CFO effective immediately -
07/26/16 02:41 PMBiocept Inc.: Biocept to Release Second Quarter Financial Results on August 2, 2016 and Host Investor Conference ... - The Wall Street Transcript
07/26/16 02:41 PMHC Stocks Judgment: Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), Biocept Inc (NASDAQ:BIOC) - share market updates (press release)
07/25/16 07:18 AMBiocept to Release Second Quarter Financial Results on August 2, 2016 and Host Investor Conference Call at 11:00 a.m. Eastern Time - [at noodls] - SAN DIEGO, July 25, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces ...
07/23/16 07:04 AMIs $2.5 Price Target Attainable For Biocept, Inc. (NASDAQ:BIOC)? - Investor Newswire
07/21/16 12:49 PMETF’s with exposure to Biocept, Inc. : July 21, 2016 -
07/21/16 11:20 AMLiquid Biopsy Market Worth 1.66 Billion USD by 2021
07/20/16 03:10 PMGlaxoSmithKline (Egypt) : Neutral outlook but great fundamentals -
07/19/16 03:20 PMGlaxoSmithKline (Egypt): Price momentum supported by strong fundamentals -
07/16/16 08:25 AMStrong Sell Calls For Biocept, Inc. (NASDAQ:BIOC) At 0 - Investor Newswire
07/15/16 01:24 PMNew Broker Ratings For Biocept, Inc. (BIOC) - FTSE News
07/13/16 02:49 PMHC Stocks Buzzer: Biocept Inc (NASDAQ:BIOC), CytRx Corporation (NASDAQ:CYTR) - share market updates (press release)
07/12/16 08:18 PMHC Stocks Review: Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), Biocept Inc (NASDAQ:BIOC) - share market updates (press release)
07/08/16 07:55 PMIs $2.5 Within Reach For Biocept, Inc. (NASDAQ:BIOC)? - Investor Newswire
07/07/16 08:04 PMBIOCEPT INC : Change in Directors or Principal Officers (form 8-K)
07/07/16 03:30 PMBIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers -
07/05/16 02:50 PMGlobal Circulating Tumor Cells (CTC) Technologies Market 2016 – ANGLE plc, Biocept Inc., Abnova Corporation ... - Patriarc
07/05/16 08:59 AMBiocept Gets Japanese Patent Covering Microchannel And Antibody Capture -
07/05/16 06:11 AMBiocept Granted Japanese Patent Covering Microchannel and Antibody Capture - [at noodls] - SAN DIEGO, July 5, 2016 /PRNewswire/ -- Biocept, Inc.(NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces ...
07/04/16 02:46 PMBiocept, Inc. (BIOC) Broker Price Targets For The Coming Week - Fiscal Standard
07/02/16 10:29 AMBiocept, Inc. (NASDAQ:BIOC) Expected to Reach Highs Of $2.5 - Investor Newswire
06/29/16 07:56 PMBIOCEPT INC : Submission of Matters to a Vote of Security Holders (form 8-K)
06/29/16 03:11 PMBIOCEPT INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/29/16 06:11 AMBiocept Comments on Reimbursement Provisions in CMS' Final PAMA Rule - [at noodls] - SAN DIEGO, June 29, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to profile and monitor patients diagnosed with cancer, ...
06/25/16 05:50 AMStrong Sell Calls Recommendations For Biocept, Inc. (NASDAQ:BIOC) At 0 - Investor Newswire
06/24/16 02:51 PMBiocept, Inc. (BIOC) Updated Price Targets - FTSE News
06/21/16 02:46 PMRecently Issued Stock Ratings For Biocept, Inc. (BIOC) - Fiscal Standard
06/18/16 07:33 AMStrong Buy Calls Count For Biocept, Inc. (NASDAQ:BIOC) At 2 - Investor Newswire
06/15/16 07:39 AMCirculating Tumor Cells Market Analysis, Trends, Size, Share, Investment Opportunities and Forecast to 2022
06/14/16 02:48 PMGlobal Cell-Free DNA Testing Market - Forecast to 2022; New Report Launched
06/13/16 03:04 PMIQ4I Research & Consultancy Published a New Report on “Cell-Free DNA (cfDNA) Testing Global Market – Forecast To 2022”
06/08/16 11:21 AMGlobal Single-Cell Genomics Industry Forecast to 2021 with Key Companies Profile, Supply, Demand, Cost Structure, and SWOT Analysis
06/06/16 12:42 PMBiocept Is An Emerging Leader In Liquid Biopsy; Roth Starts At Buy - Roth Capital Partners analyst, Chris Lewis, believes that Biocept Inc (NASDAQ: BIOC) is an emerging leader in Liquid Biopsy. Therefore, he initiated coverage on the stock with a rate of Buy and kept a price tag of $1.20. The brokerage thinks that through its proprietary technology platform, Biocept, it is capable of assaying both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), strong IP portfolio, notable collaborations with leading cancer institutions, and building commercial momentum. "Therefore," Lewis said, "we believe Biocept ...Full story available on Benzinga.com
06/06/16 10:12 AMHealthcare New Lows: Sequenom Inc. (NASDAQ:SQNM), Biocept, Inc. (NASDAQ:BIOC), EndoChoice Holdings, Inc ... - KC Register
06/06/16 07:19 AMCoverage initiated on Biocept by ROTH Capital -
06/05/16 10:42 AMHealthcare Stocks to watch: Flexion Therapeutics, Inc. (NASDAQ:FLXN) , Biocept, Inc. (NASDAQ:BIOC) - Is stories
06/03/16 11:25 AMSizzling HC Stocks Update: Biocept Inc (NASDAQ:BIOC), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - share market updates (press release)
06/02/16 02:58 PMBiocept, Inc. (NASDAQ:BIOC) Yearly Sales Estimate At $14.25 - Stocks Daily - Biocept, Inc. (NASDAQ:BIOC) Yearly Sales Estimate At $14.25Stocks DailyAs many as 2 analysts, the mean yearly sales forecast for Biocept, Inc. (NASDAQ:BIOC) stands at $14.25 and the median is $14.25 for the period closed 4. The lower band of sales forecast is $7.3 and the higher band is $21.2, showing a standard deviation ...Analyst Review: Biocept, Inc. (BIOC)Risers & FallersBiocept Incorporated (NASDAQ:BIOC) Shorted Shares Increased By 18.18%HNNall 3 news articles »
05/31/16 02:52 PMYY Inc (ADR) (NASDAQ:YY) Edged Up 1.33%: Biocept, Inc. (NASDAQ:BIOC), Alon USA Energy, Inc. (NYSE:ALJ ... - KC Register - YY Inc (ADR) (NASDAQ:YY) Edged Up 1.33%: Biocept, Inc. (NASDAQ:BIOC), Alon USA Energy, Inc. (NYSE:ALJ ...KC RegisterOn 23 May, Biocept, Inc. (NASDAQ:BIOC) announces that it has entered into a master services agreement with a biopharmaceutical company to develop targeted liquid biopsy tests for multiple tumor types and molecular targets. The agreement includes ...Biocept (BIOC) Announces Commercial Launch of PD-L1StreetInsider.comall 3 news articles »
05/31/16 10:14 AMHealthcare Lows: Biocept, Inc. (NASDAQ:BIOC), MetLife, Inc. (NYSE:MET), Merck & Co. Inc. (NYSE:MRK), Greatbatch ... - KC Register - Healthcare Lows: Biocept, Inc. (NASDAQ:BIOC), MetLife, Inc. (NYSE:MET), Merck & Co. Inc. (NYSE:MRK), Greatbatch ...KC RegisterOn 23 May, Biocept, Inc. (NASDAQ:BIOC) announced that it has entered into a master services agreement with a biopharmaceutical company to develop targeted liquid biopsy tests for multiple tumor types and molecular targets. The agreement includes ...
05/31/16 10:14 AMStocks Update: Minerva Neurosciences, Inc (NASDAQ:NERV) , Biocept, Inc. (NASDAQ:BIOC) - Is stories - iStreetWireStocks Update: Minerva Neurosciences, Inc (NASDAQ:NERV) , Biocept, Inc. (NASDAQ:BIOC)Is storiesMinerva Neurosciences, Inc (NASDAQ:NERV) decreased -4.07% to $11.32 while traded 7.61 million shares on 5/27/2016. The stock price negotiated for value between $10.60 to $12.18 in recent trading session. During the past 52 weeks, the stock's price ...Healthcare Unusual Volume: Minerva Neurosciences, Inc. (NASDAQ:NERV), Atossa Genetics, Inc. (NASDAQ:ATOS ...Benchmark Monitorall 14 news articles »
05/31/16 06:02 AMBiocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test - [at noodls] - SAN DIEGO, May 31, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces ...
05/28/16 12:02 PMHealthcare Stock to Lookout: Biocept Inc (NASDAQ:BIOC) - The Point Review - The Point ReviewHealthcare Stock to Lookout: Biocept Inc (NASDAQ:BIOC)The Point ReviewShare of Biocept Inc (NASDAQ:BIOC) traded on -10.47 percent below secure line at 2:30PM EDT in order to take the company's stock at the price of $0.612. At the time of writing the stock exchanged hands 926,921.00 shares versus average trading capacity ...Notable 52-Week Highs and Lows 5/27: (BIG) (VEEV) (ULTA) High; (BIOC) (IONS) (IPCI) LowStreetInsider.comall 2 news articles »
05/26/16 06:20 PMETF’s with exposure to Biocept, Inc. : May 26, 2016 -
05/26/16 03:01 PMBIOCEPT INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Trans -
05/26/16 12:08 PMAnalysts Offer Insights on Healthcare Companies: Biocept Inc. (NASDAQ: BIOC), SAGE Therapeutics Inc (NASDAQ ... - Markets.co - Analysts Offer Insights on Healthcare Companies: Biocept Inc. (NASDAQ: BIOC), SAGE Therapeutics Inc (NASDAQ ...Markets.coCompanies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biocept Inc. (NASDAQ: BIOC), SAGE Therapeutics Inc (NASDAQ: SAGE) and Nanosphere (NASDAQ: NSPH). Biocept Inc. (NASDAQ: BIOC). In a report ...

Social

About Biocept

Biocept logoBiocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid, assays utilizing a standard blood sample, or liquid biopsy. The Company offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer and melanoma. The Company offers OncoCEE-BR for breast cancer, OncoCEE-LU for both non-small cell lung cancer and small cell lung cancer, OncoCEE-ME for melanoma and OncoCEE-GA for gastric cancer. These assays utilize the Company's CEE technology platform and provide CTC enumeration, as well as biomarker analysis. The Company's breast, lung and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on characteristics of their patients' tumors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BIOC
  • CUSIP:
Key Metrics:
  • Previous Close: $0.68
  • 50 Day Moving Average: $0.6417
  • 200 Day Moving Average: $1.0666
  • P/E Ratio: N/A
  • P/E Growth: -0.0200
  • Market Cap: $16.86M
  • Beta: 2.05
  • Current Year EPS Consensus Estimate: $0.4000 EPS
  • Next Year EPS Consensus Estimate: $-0.4400 EPS
Additional Links:
Biocept (NASDAQ:BIOC) Chart for Thursday, July, 28, 2016